🚀
Enjoy a 7-Day Free Trial Thru Dec 05, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Drug Manufacturers
Amgen Inc (XTER:AMG)
News
Amgen Inc
XTER
:AMG (USA) Â
Ordinary Shares
€ 265.40
(+6.08%)
Nov 27
On watch
P/E:
35.86
P/B:
20.00
Market Cap:
€ 143.51B
($ 151.32B)
Enterprise V:
€ 192.49B
($ 202.97B)
Volume:
2.61K
Avg Vol (2M):
795.00
Warning! GuruFocus detected 6 Severe warning signs with AMG.
Try a 7-Day Free Trial
to check it out.
Trade In:
Volume:
2.61K
Market Cap €:
143.51B
Market Cap $:
151.32B
PE Ratio:
35.86
Avg Vol (2M):
795.00
Enterprise Value €:
192.49B
Enterprise Value $:
202.97B
PB Ratio:
20.00
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Amgen Inc (XTER:AMG) Stock News, Headlines & Updates
Amgen Inc Stock News from GuruFocus
Total 39
1
Nov 26, 2024
Amgen (AMGN) Shares Plunge Over 10% After Obesity Drug Trial Results Disappoint
GuruFocus News
•
10:11am
Amgen Inc (AMGN) Trading Down 11.91% on Nov 26
GuruFocus News
•
10:00am
US Markets React to Tariff Policies; AMGN and BBY Stocks Drop
GuruFocus News
•
9:20am
Amgen's (AMGN) Obesity Drug MariTide Faces Market Disappointment
GuruFocus News
•
7:50am
AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
PRNewswire
•
7:00am
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
PRNewswire
•
7:00am
Nov 22, 2024
Amgen's (AMGN) Experimental Drug MariTide Faces Crucial Phase 2 Results
GuruFocus News
•
6:53am
Nov 20, 2024
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
PRNewswire
•
4:00pm
Nov 16, 2024
Amgen Inc (AMGN) Stock Price Down 4.16% on Nov 16
GuruFocus News
•
4:56am
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Marketwired
•
8:00pm
Nov 14, 2024
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
PRNewswire
•
4:00pm
Nov 13, 2024
MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM
PRNewswire
•
3:00pm
Amgen (AMGN) Clarifies: No Link Between Weight Loss Drug and Bone Density Changes
GuruFocus News
•
8:32am
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
PRNewswire
•
5:00am
Nov 12, 2024
AMGN Stock Drops 5% Amid Industry Decline and Earnings Report
GuruFocus News
•
2:33pm
Nov 08, 2024
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
PRNewswire
•
4:00pm
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
PRNewswire
•
2:00am
Nov 01, 2024
The Art of Valuation: Discovering Amgen Inc's Intrinsic Value
GuruFocus News
•
6:00am
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
GuruFocus News
•
11:03pm
Oct 31, 2024
Amgen Inc (AMGN) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Pipeline Advancements
GuruFocus News
•
1:21am
Q3 2024 Amgen Inc Earnings Call Transcript
GuruFocus News
•
12:11am
Oct 30, 2024
AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
PRNewswire
•
4:00pm
Amgen Inc (AMGN) Q3 2024 Earnings: Revenue Surges to $8.5 Billion, GAAP EPS Climbs to $5.22, Exceeding Estimates
GuruFocus News
•
3:43pm
Oct 25, 2024
AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND
PRNewswire
•
4:00pm
Oct 24, 2024
AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS
PRNewswire
•
4:00pm
Oct 15, 2024
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
PRNewswire
•
8:00am
Oct 14, 2024
Amgen Downgraded to ?Hold? by Truist as Competitive Pressures Loom
Muslim Farooque
•
11:24am
Amgen (AMGN) Stock Faces Pressure Amid Analyst Downgrade
GuruFocus News
•
9:50am
Oct 08, 2024
The Art of Valuation: Discovering Amgen Inc's Intrinsic Value
GuruFocus News
•
6:00am
Oct 02, 2024
Moore Law, PLLC Encourages Amgen, Inc. Investors to Contact Law Firm
Marketwired
•
6:00pm
Oct 01, 2024
LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
PRNewswire
•
9:00am
Sep 25, 2024
Amgen Inc (AMGN) Shares Gap Down to $315.31 on Sep 25
GuruFocus Research
•
11:01am
Sep 24, 2024
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
PRNewswire
•
4:00pm
Sep 23, 2024
AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
PRNewswire
•
4:00pm
Unlocking Intrinsic Value: Analysis of Amgen Inc
GuruFocus Research
•
6:01am
Sep 13, 2024
AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024
PRNewswire
•
9:00am
Sep 09, 2024
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRAâ„¢ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
PRNewswire
•
9:00am
Amgen Inc: An Exploration into Its Intrinsic Value
GuruFocus Research
•
6:00am
Aug 30, 2024
AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE
PRNewswire
•
4:00pm
Total 39
1
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news